Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus

Archives of Surgery

Volumn 132, Issue 7, 1997, Pages 728-733

  Katada, Natsuya ^a   Hinder, Ronald A ^c   Smyrk, Thomas C ^b   Hirabayashi, Naoki ^a   Perdikis, Galen ^a   Lund, Richard J ^a   Woodward, Timothy ^c   Klingler, Paul J ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clarkson Hospital   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

EID: 0030829281     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430310042007     Document Type: Article

References (29)

1. Thompson WG, Heaton KW. Heartburn in apparently healthy people, J Can Med Assoc. 1982;126:46-48.
2. Lund O, Hasenkam JM, Aagaard MT, Kimose HH. Time-related changes in characteristics of prognostic significance of carcinomas of the oesophagus and cardia. Br J Surg. 1989;76:1301-1307.
3. Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev. 1992;11:179-195.
4. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer. 1994;73:2900- 2904.
5. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995;55:1811-1816.
6. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol. 1995;146:20-26.
7. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer. 1995;75:2209-2213.
8. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
9. Wijsman JH, Jonker RR, Keijzer R, Van De Velde CJH, Cornelisse CJ, Van Dierendonck JH. A new method to detect apoptosis in paraffin sections: in situ end- labeling of fragmented DNA. J Histochem Cytochem. 1993;41:7-12.
10. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol. 1993; 170:1-8.
11. Korsmeyer SJ. bcl-2 Initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
12. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev. 1992;11:141-148.
13. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83:5214-5218.
14. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
15. Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatln cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol. 1984;142:67-77.
16. Martz E, Howell DM. CTL: virus control cells first and cytolytic cells second? Immunol Today. 1989;10:79-86.
17. Shi Y, Szalay MG, Paskar L, Boyer M, Singh B, Green DR. Activation-induced cell death In T-cell hybridomas is due to apoptosis: morphologic aspects and DNA fragmentation. J Immunol. 1990;144:3326-3333.
18. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate- binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell. 1991;67:629-639.
19. Kasagl N, Gomyo Y, Shirai H, Tsujitani S, Ito H. Apoptotic cell death in human gastric carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling. Jpn J Cancer Res. 1994;85:939-945.
20. Koide N. Histochemical study on cell proliferation and cell death in esophageal carcinoma [In Japanese]. Shinshu Igaku. 1994;42:379-388.
21. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991;88.6961-6965.
22. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol. 1993;142:743-753.
23. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G. p53 Immunoreactivity in Barren's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg. 1994;108:1132-1137.
24. Krishnadath KK, Tilanus HW, Blankenstein MV, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barren's oesophagus. J Pathol. 1995;175:175-180.
25. Vogelstein B, Kinzler K. p53 function and dysfunction. Cell. 1992;70:523-526.
26. Miyashita T, Krajewski S, Krajewski M, et al. Tumor supressor p53 is a regulator of bcl-2 and baxgene expression in vitro and in vivo. Oncogene. 1994;9:1799-1805.
27. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994;211:90-98.
28. Smyrk TC. Histology in the diagnosis of foregut disease. In: Hinder RA, ed. Problems in General Surgery. Philadelphia, Pa: JB Lippincott Co; 1992;9:14-38.
29. Katada N, Hirabayashi N, Hinder PR, et al. Duodeno-esophageal reflux induces apoptosis In rat esophageal mucosa. Gastroenterology. 1996;110:A150. Abstract.